Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: Postmarketing surveillance data in England

Drug Safety

Volumn 26, Issue 8, 2003, Pages 589-597

  Wilton, Lynda V ^a,b   Kollarova, Monika ^c   Heeley, Emma ^a   Shakir, Saad A ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; AZITHROMYCIN; CEFIXIME; CIPROFLOXACIN; FLUOXETINE; FLUVOXAMINE; FOSFOMYCIN; NEFAZODONE; NORFLOXACIN; OFLOXACIN; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; VAGINA CANDIDIASIS;

ADULT; ANTI-INFECTIVE AGENTS; ANTIDEPRESSIVE AGENTS; CANDIDIASIS, VULVOVAGINAL; COHORT STUDIES; ENGLAND; FEMALE; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK;

EID: 0038310868     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326080-00005     Document Type: Article

References (21)

1. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985; 152 (7 Pt 2): 924-35
2. Sobel J. Candidal vulvovaginitis. Clin Obstet Gynecol 1993; 36: 153-65
3. Galask RP. Vaginal colonization by bacteria and yeast. Am J Obstet Gynecol 1988; 158: 993-5
4. Khan ZK, Gyanchandani A. Candidiasis: a review. Proc Indian Natl Sci Acad Part B 1998; 64: 1-34
5. Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J 1991 Sep; 11 (3): 319-26
6. Spinillo A, Capuzzo E, Acciano S, et al. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 1999; 180 (1 Pt 1): 14-7
7. MacDonald TM, Beardon PH, McGilchrist MM, et al. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med 1993 Jul; 86 (7): 419-24
8. Iravani A, Bischoff W. Antibiotic therapy for urinary tract infections. Am J Med 1992; 92: 6A-100S
9. Leigh DA, Joy GE, Tait S, et al. Treatment of acute uncomplicated urinary tract infections with single daily doses of cefuroxime axetil. J Antimicrob Chemother 1989; 23 (2): 267-73
10. Goldstein EJ, Kahn RM, Alpert ML, et al. Ciprofloxacin versus cinoxacin in therapy of urinary tract infections: a randomized, double-blind trial. Am J Med 1987; 82 (4A): 284-7
11. Iravani A, Richard GA. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Agents Chemother 1986; 29 (1): 107-11
12. Mann RD. Prescription-event monitoring: recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201
13. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences/World Health Organization, 1993
14. Guidelines on the practice of ethical committees in medical research involving human subjects. London: Royal College of Physicians of London, 1996 Aug
15. Kliment M, Korbel M, Hrúzik P, et al. Etiologia patogenéza a diagnostika akútnej a recidivujúcej vulvovaginálnej kandidozy. Praktická gynekológia 1998; 5 (1): 1-7
16. Sobel JD. Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women. Obstet Gynecol 1996; 88 (4 Pt 2): 704-6
17. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996; 7 (2): 182-7
18. Spinillo A, Capuzzo E, Nicola S, et al. The impact of oral contraception on vulvovaginal candidiasis. Contraception 1995; 51 (5): 293-7
19. Goldacre MJ, Watt B, Loudon N, et al. Vaginal microbial flora in normal young women. BMJ 1979; 1: 1450-3
20. Clark WJ, Layton D, Wilton LV, et al. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibiotics; experience from large cohorts from the drug safety research unit prescription-event monitoring database. Drug Saf 2001; 24 (15): 1143-54
21. McAvoy BR, Kramer EFS. General practice postal surveys: a questionnaire too far? BMJ 1996; 33: 732-3